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Abstract
The peripheral terminals of primary sensory neurons detect histamine and non-histamine itch-
provoking ligands through molecularly distinct transduction mechanisms. It remains unclear,
however, whether these distinct pruritogens activate the same or different afferent fibers. We
utilized a strategy of reversibly silencing specific subsets of murine pruritogen-sensitive sensory
axons by targeted delivery of a charged sodium-channel blocker and found that functional
blockade of histamine itch did not affect the itch evoked by chloroquine or SLIGRL-NH2, and
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vice versa. Notably, blocking itch-generating fibers did not reduce pain-associated behavior.
However, silencing TRPV1+ or TRPA1+ neurons allowed AITC or capsaicin respectively to evoke
itch, implying that certain peripheral afferents may normally indirectly inhibit algogens from
eliciting itch. These findings support the presence of functionally distinct sets of itch-generating
neurons and suggest that targeted silencing of activated sensory fibers may represent a clinically
useful anti-pruritic therapeutic approach for histaminergic and non-histaminergic pruritus.
Itch is a complex unpleasant cutaneous sensation that in some respects resembles pain, yet is
different in terms of its intrinsic sensory quality and the urge to scratch. Histamine-mediated
itch, as in patients with urticaria, can be effectively treated using histamine receptor
antagonists1. However, itch accompanying most chronic pruritic diseases, including atopic
dermatitis (eczema)2, allergic itch3 and dry skin itch4, is not predominantly mediated by
histamine5. The G-protein coupled receptors responsive to specific itch-generating ligands
are distinct, although at a cellular level, there is overlapping responsiveness of trigeminal
and dorsal root ganglia (DRG) neurons to itch-producing pruritogens and pain-producing
algogens6–9. Histamine-sensitive H1 receptors (H1Rs) generate histamine itch and are
expressed by TRPV1+/phospholipase-β-3 (PLCβ3)+ fibers10,11. Itch evoked by chloroquine
is mediated by Mas-related G-protein-coupled receptor (Mrgpr) A36,12, while MrgprC11 is
sensitized in dry skin itch9,13 and activated by pruritogens released from mast cells during
allergic itch3. Notably, co-activation of TRPV1 and H1R is required to produce histamine
itch14, while MrgprA3- or C11-mediated itch requires co-activation of TRPA112 even
though each of these TRP channels are canonical nociceptor transducers. In vitro calcium
imaging experiments find that neurons expressing MrgprA3 also respond to histamine,
which is interpreted as indicating a single neuronal path for histaminergic and MrgprA3-
dependent itch6. Supporting this, ablation of neurons expressing MrgprA3 reduces the
scratching evoked by histamine, chloroquine, dry skin, and allergic inflammation15.
However, others report separate neural pathways mediating histamine and certain types of
non-histamine itch16,17. Furthermore, while primary sensory neurons of juvenile mice
respond to multiple itch mediators, this non-specificity decreases with age18. It remains
controversial, therefore, if in the adult there are separate afferents that mediate histamine
itch and MrgprA3-dependent non-histamine itch. This distinction is clinically important
since therapies targeting histaminergic itch fibers might be ineffective for treating non-
histaminergic itch if the neurons mediating the two itches are functionally distinct in the
adult.
To study if histaminergic and non-histaminergic itch are functionally distinct we adapted a
method originally designed for achieving a pain-specific peripheral nerve block19,20 to
selectively silence the peripheral terminals of different subsets of pruritogen- and algogen-
responsive primary afferents in an activity-dependent manner. To do this we targeted the
charged, membrane-impermeable lidocaine derivative N-ethyl-lidocaine (QX-314) (a
sodium channel blocker) through large pore ion channels activated specifically by different
algogens and pruritogens.
RESULTS
Targeted Na+ current block of pruritogen-activated neurons
Activation of TRPV1 channels permits entry of QX-314 selectively into dorsal root ganglion
(DRG) and trigeminal ganglion nociceptors through the TRPV1 pore to produce a selective
block of sodium currents only in TRPV1 expressing nociceptors19–24. Here we examined
whether histamine-mediated activation of TRPV1 channels11,14 would allow sufficient
QX-314 uptake to suppress sodium channel currents selectively in histamine-responsive
trigeminal ganglion neurons. In trigeminal neuron cultures from adult male CD-1 mice we
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recorded sodium currents using whole cell voltage clamp from small (<25 μm diameter)
neurons that showed an increase in intracellular calcium concentration upon a 60 second
bath application of 100 μM histamine (Fig. 1a). In these cells, a subsequent 2.5 minute
application of 100 μM histamine together with 5 mM QX-314 significantly and
progressively decreased sodium current amplitude with a nearly complete block after 10
minutes (Fig. 1b,c and Supplementary Tables 1 and 2). This decrease was prevented by the
TRPV1- channel blocker capsazepine (20 μM) (Fig. 1c). Sodium currents recorded from
trigeminal neurons that did not respond to histamine were not affected by co-application of
histamine and QX-314 (Fig. 1b,c), indicating that extracellularly applied QX-314 by itself at
this dose has no activity. Together with previous studies demonstrating that histamine
produces downstream activation of TRPV1 channels14, our data indicate that QX-314 enters
histamine responsive trigeminal neurons when activated by histamine, likely through
TRPV1 channels.
We then examined whether we could block sodium currents in chloroquine-responsive
trigeminal neurons by co-application of chloroquine and QX-314. TRPA1 channels are
activated by chloroquine in these cells12. We and others have demonstrated that QX-314 and
other cationic organic compounds with a similar molecular weight permeate the TRPA1
pore23,25. In trigeminal neurons that showed a robust increase in intracellular calcium after
brief chloroquine application (100 μM, 60 seconds) (Fig. 1d and Supplementary Tables 3
and 4), subsequent co-application of 100 μM chloroquine and 5 mM QX-314 significantly
decreased sodium currents (Fig. 1e,f). This effect was significantly reduced by pre-
incubation with the TRPA1-channel blocker HC-030031 (100 μM) (Fig. 1f). In cells that did
not respond to chloroquine, QX-314 and chloroquine had no effect on sodium current (Fig.
1e,f).
Pruritogen-mediated activation of TRP channels (histamine for TRPV1 and chloroquine for
TRPA1) permitted, therefore, sufficient entry of QX-314 selectively into particular
pruritogen-sensitive trigeminal neurons to block sodium currents only in these neurons
(Supplementary Fig. 1).
Selective silencing of pruriceptors in vivo
To test if we could selectively silence pruriceptors in vivo we used intradermal cheek
injections of pruritogens together with QX-314, then characterized pruriceptor function by
quantifying ensuing itch behavioral responses (hindlimb scratching of cheek) or pain
(forelimb wiping of cheek)26. Intradermal injection of histamine (100 μg/20 μl) produced
scratching (64.3 ± 7.5 bouts, n = 6) that fully resolved within 30 minutes. There was no
significant change in scratching (56.0 ± 8.3 bouts, n = 6; P > 0.05) when histamine was
injected together with 1% QX-314. Based on the delayed time course of nociceptor block in
vivo in response to a combination of capsaicin and QX-31419, and considering the gradual
development of full sodium current block in vitro after QX-314 and histamine
coadministration (Fig. 1c), we hypothesized that the short duration of histamine-evoked
scratching behavior (~25 minutes) was too brief to detect the slow onset blocking effects
generated by coadministration of histamine with QX-314. To test this we devised a
behavioral model using two sequential intradermal injections, 30 minutes apart, of a
pruritogen into the same intradermal cheek-injection site. Identical pruritogen doses were
used in each injection. To ensure that both injections were distributed within the same
cutaneous area, however, the first dose (conditioning injection) was delivered in 20 μl of
vehicle while the second dose (test injection) was administered in 10 μl (Supplementary Fig.
2). Only behavior evoked by the test (second) injection was compared to behavior evoked by
other identical test injections, with the experimental variable being the identity of the
conditioning (first) injection given 30 minutes earlier.
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When histamine alone was given for the conditioning injection (100 μg/20 μl) and again 30
minutes later for the test injection (100 μg/10 μl) at the same site, the amount of scratching
evoked by the two injections was not significantly different (Fig. 2a). However, histamine-
evoked scratching was effectively abolished 30 minutes after a conditioning injection of
histamine and QX-314 together (Fig. 2b), but not when preceded by injection of QX-314
alone (Supplementary Fig. 3a). We conclude that histamine-mediated activation of large
pore channels, such as TRPV114, permitted uptake of QX-314, to produce a slow (<30
minutes) onset electrical silencing of the histamine-responsive sensory fibers, which then
blocked the response to subsequent injection of histamine (Fig. 2b).
Based on our in vitro results (Fig. 1d–f) we hypothesized that intradermal administration of
chloroquine with QX-314 could block chloroquine itch by permitting selective uptake of
QX-314 through chloroquine-mediated activation of TRPA112. Co-injection of QX-314
together with chloroquine (50 μg/20 μl) inhibited scratching produced by subsequent
chloroquine (50 μg/10 μl) test injection, while injection of chloroquine alone or QX-314
alone did not (Fig. 2c,d and Supplementary Fig. 3b). We conclude that large-pore channels
downstream of chloroquine-evoked MrgprA3 activation, likely TRPA112, permitted
selective uptake of QX-314 and subsequent electrical silencing of chloroquine-sensitive
afferent fibers.
SLIGRL-NH2 (SLIGRL) acts at MrgprC11 receptors to produce itch9. MrgprC11-mediated
itch also requires TRPA1 activation to generate scratching behavior12. We next explored,
therefore, whether SLIGRL-mediated activation of TRPA1 channels is sufficient to
introduce QX-314 and inhibit subsequent SLIGRL-evoked itch. SLIGRL (50 μg) evoked
scratching bouts were inhibited 30 minutes after injection of QX-314 together with SLIGRL,
but not after injections of SLIGRL alone or QX-314 alone (Fig. 2e,f and Supplementary Fig.
3c).
These findings demonstrate that histaminergic and non-histaminergic pruritogen-mediated
entry of QX-314 into pruriceptors is sufficient to block activity of itch-generating fibers, as
measured by a reduction in scratching behavior on subsequent injection of the same
pruritogen.
Pruriceptors are dispensable for non-itch sensations
It is unclear whether fibers that mediate histamine itch contribute to normal chemical,
thermal and mechanical pain sensitivity. To explore this, we assessed pain-related
behavioral responses to noxious chemical, thermal, and mechanical stimulation after co-
injection of QX-314 together with chloroquine (50 μg), histamine (100 μg), capsaicin
(0.1%), or AITC (0.15%). Injection of capsaicin in the cheek evoked robust forelimb wiping
(indicative of TRPV1-evoked pain) 30 minutes after vehicle (0.9% NaCl) injection (Fig. 3a).
Administration of QX-314 together with capsaicin, as expected, abolished subsequent
capsaicin-evoked wiping (Fig. 3a). However, capsaicin-evoked wiping was unchanged 30
minutes after injection of QX-314 together with either histamine or chloroquine (Fig. 3a),
even though such injections block scratching generated by these pruritogens (Figs. 2 and 4).
Injections of histamine, chloroquine, or QX-314 alone did not reduce subsequent capsaicin-
evoked wiping (Supplementary Fig. 4a).
Test injection of AITC (0.15%) evoked robust forelimb wiping (indicative of TRPA1-
evoked pain) 30 minutes after vehicle (0.9% NaCl) injection (Fig. 3b). AITC-evoked wiping
was blocked after a conditioning injection of QX-314 together with AITC (0.15%), but not
after conditioning injections of QX-314 together with chloroquine (50 μg), or histamine
(100 μg), or by prior administration of QX-314, chloroquine, or histamine alone (Fig. 3b and
Supplementary Fig. 4b).
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We next asked whether blocking histamine- or chloroquine-responsive fibers affects
mechanical or thermal pain sensitivity. Intraplantar co-injection of QX-314 (20 μl) together
with histamine (100 μg) or chloroquine (50 μg) had no effect on mechanical sensitivity to
von Frey filaments, while co-application of capsaicin (0.1%) and QX-314 abolished
mechanical pain responses (Fig. 3c). Likewise, intraplantar injection of QX-314 (20 μl)
together with histamine (100 μg) or chloroquine (50 μg) did not alter responses to noxious
heat (52° C). Noxious thermal sensitivity was, however, abolished when tested after
coadministration of capsaicin (0.1%) and QX-314 (Fig. 3d).
To determine whether histamine and chloroquine itch-generating fibers are dispensable for
sensitivity to cold or tactile stimuli, we performed the focal cold plantar assay27 and the
adhesive dot plantar tactile assay28 30 minutes after intraplantar injections of pruritogens
and algogens together with QX-314 (Fig. 3e,f). Cold sensitivity was unaltered 30 minutes
after injections of QX-314 together with histamine (100 μg), chloroquine (50 μg), or
capsaicin (0.1%). However, cold sensitivity was significantly reduced after co-injection of
AITC (0.15%) and QX-314 (Fig. 3e). We next used latency to attend to an adhesive dot
placed on the plantar paw surface as a measure of tactile sensitivity28. The latency to attend
was unchanged 30 minutes after injections of QX-314 with histamine (100 μg), chloroquine
(50 μg), capsaicin (0.1%), or AITC (0.15%), while intraplantar injection of lidocaine (5%)
significantly increased the latency (Fig. 3f).
We propose that while histamine and chloroquine activate TRPV1 and TRPA1 expressing
pruriceptors, respectively, these fibers are not essential for acute thermal, mechanical and
chemical pain sensitivity, which likely involve different or additional subsets of afferents to
generate pain-related behavior. Likewise, we conclude that chloroquine- and histamine-
sensitive itch fibers are not essential for normal tactile sensitivity.
Distinct fibers mediate histamine and non-histamine itch
We next used the silencing strategy to reveal whether different pruritogens activate the same
or unique peripheral afferent pathways by administering test injections (10 μl) of histamine
(100 μg), chloroquine (50 μg) or SLIGRL (50 μg), 30 minutes after conditioning injections
(20 μl) of histamine (100 μg), chloroquine (50 μg) or SLIGRL (50 μg) with and without
QX-314. We hypothesized that if histaminergic and non-histaminergic itch are transmitted
by different subsets of afferent fibers, application of histamine together with QX-314 will
block histaminergic itch while chloroquine or SLIGRL itch will remain intact, and vice
versa.
We first examined whether histamine-evoked scratching is affected by the targeted silencing
of chloroquine-activated pruriceptors. Histamine-evoked scratching was unchanged 30
minutes after a conditioning injection of chloroquine and QX-314 together (Fig. 4a), even
though this treatment blocked subsequent chloroquine itch (Fig. 2b and 4b). Similarly,
conditioning injection of SLIGRL with QX-314 (which reverses later SLIGRL-evoked
scratching; Fig. 2c and 4c) did not reduce subsequent histamine (100μg/10μl) itch (Fig. 4a).
We then asked if chloroquine itch is affected upon silencing of histamine- or SLIGRL-
sensitive itch fibers by injecting chloroquine thirty minutes after administration of QX-314
together with either histamine or SLIGRL. Chloroquine-evoked itch was blocked after
coinjection of SLIGRL and QX-314, but not by coadministration of histamine and QX-314
(Fig. 4b). Likewise, SLIGRL-evoked itch was unaffected 30 minutes following injection of
histamine with QX-314, but was significantly reduced after injection of chloroquine and
QX-314 (Fig. 4c).
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It appears that a common afferent population mediates chloroquine and SLIGRL itch, but
that this population is functionally distinct from neurons responsible for histamine itch.
These findings contrast, however, with prior in vitro data showing that all chloroquine-
responsive DRG neurons respond to histamine6. A possible explanation for this discrepancy
is that peripheral terminals of trigeminal neurons differ from DRG neuron cell bodies in
terms of their responsiveness to multiple pruritogens. To explore this, we repeated the same
silencing strategy on the back below the neck. Treatment with histamine and QX-314
together did not reduce subsequent chloroquine-evoked scratching when compared to
treatment with vehicle, while intradermal injection of chloroquine and QX-314 together
inhibited subsequent chloroquine-evoked scratching (Supplementary Fig. 5) indicating that
facial and somatic itch appear to be similar in terms of the functional independence of
histamine and non-histamine itch.
Another possibility is that different pruriceptor subsets exist with high or low sensitivity to
either histamine or non-histamine pruritogens. To investigate this we varied the dose of
pruritogen given with 1% QX-314 (20 μl) for conditioning injections. Application of a lower
dose of histamine (10 μg) together with QX-314 inhibited subsequent histamine-evoked
scratching without reversing chloroquine (50 μg) scratching (Fig. 4a,b), essentially identical
to the effects following a higher dose of histamine (100 μg) with QX-314. However,
increasing the concentration of histamine to 108.7 mM (400 μg/20 μl) with QX-314 for
conditioning injections blocked scratching evoked by both histamine and chloroquine (Fig.
4a,b) indicating that an overlap manifests only at very high doses of histamine.
Higher doses of chloroquine (200 μg or 400 μg) together with QX-314 blocked later
chloroquine itch behavior, but not scratching evoked by histamine. However, using 96.9
mM chloroquine (1 mg/20 μl) together with QX-314 for conditioning injections blocked
subsequent histamine- and chloroquine-evoked scratching (Fig. 4a,b).
These data suggest that histamine and chloroquine generally activate functionally distinct
pruriceptor populations, but that these fibers can respond to multiple pruritogens, either
directly or indirectly, when they are presented at very high, presumably non-
physiological29,30 concentrations (histamine, 107.8 mM; chloroquine, 96.9 mM).
Histamine and chloroquine act on different sets of neurons
The responsiveness of DRG neurons to multiple pruritogens decreases with age18. In
juvenile mice, 60–100% of all chloroquine responsive DRG cells also respond to
histamine6,18, while only half of chloroquine-responsive DRG neurons respond to histamine
in adolescent mice18. We therefore asked whether distinct chloroquine and histamine-
sensitive neuronal populations could be revealed in adult (2 to 4-month-old) mice by their
sensitivity to pruritogens in vitro. MrgprA3 receptors are activated by 10 μM chloroquine
and maximally activated by 1 mM chloroquine in HEK293 cells6. Murine DRG neurons
respond to histamine at doses as low as 10 μM14. Here, we examined coincident calcium
responses of 564 cultured trigeminal neurons to 10 μM histamine and 10 μM chloroquine.
Histamine activated 4.1% (23 of 564) of trigeminal neurons, while 3.0% (17 of 564)
responded to chloroquine (Fig. 5a). A majority of chloroquine-and histamine-responding
trigeminal neurons responded to only one pruritogen. Among chloroquine-activated cells,
76.5% (13 of 17) responded to chloroquine but not histamine, while the remaining 23.5% (4
of 17) responded to both 10 μM histamine and 10 μM chloroquine. Likewise, trigeminal
neurons responding to histamine were largely unresponsive to chloroquine: 82.6% (19 of 23)
responded to histamine but not chloroquine, and 17.4% (4 of 23) responded to both
histamine and chloroquine.
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To investigate whether responsiveness of adult trigeminal neurons to chloroquine or
histamine is dependent upon pruritogen dose, we further explored coincident calcium
responses to 100 μM histamine and 100 μM chloroquine. Most trigeminal neurons that
responded either to 100 μM histamine (4.8% of all cells) or 100 μM chloroquine (4.3% of all
cells) did not respond to both (0.9% of all cells) (Supplementary Fig. 6a). Moreover, we also
found in DRG neurons from adult mice that the populations of fibers responding to
chloroquine and histamine are, as in the trigeminal ganglia, largely distinct (Supplementary
Fig. 6b). These data demonstrate that primary afferent populations responding to histamine
and chloroquine are largely distinct in adult mice.
The requisite expression of TRPV1 for histaminergic itch14, and of TRPA1 for chloroquine-
evoked itch12 raises the question: do relative expression patterns of TRPA1 and TRPV1
differ among chloroquine- and histamine-sensitive neuronal populations? To answer this, we
exposed cultured trigeminal neurons to 100 μM AITC and 1 μM capsaicin and measured
coincident responses of neurons to both agents. Consistent with the described receptor
expression patterns for neurons that mediate histamine itch (e.g., H1R and TRPV1)10,14 and
chloroquine itch (e.g., MrgprA3 and TRPA1)6,12, we found that a majority (16 of 23,
69.6%) of histamine-responsive cells responded to capsaicin (Fig. 5b), and most (9 of 17,
52.9%) chloroquine-activated neurons were sensitive to AITC (Fig. 5c). The inverse
relationships were also true: most (14 of 23, 60.8%) histamine-responsive trigeminal cells
did not respond to AITC (Fig. 5d), and capsaicin failed to activate a majority (12 of 17,
70.6%) of chloroquine-activated neurons (Fig. 5e).
Roles of TRP channels in histamine and non-histamine itch
The different expression patterns of TRPV1 and TRPA1 among histamine and chloroquine-
sensitive neurons in vitro (Fig. 5) suggest that targeted silencing of TRPV1 or TRPA1 fibers
may differently affect histamine itch versus chloroquine itch. To explore this we
administered 20 μl conditioning injections of capsaicin (0.1%) or AITC (0.15%) with or
without QX-314 and then administered 10 μl test injections of the pruritogens histamine
(100 μg), chloroquine (50 μg) or SLIGRL (50 μg) 30 minutes later at the same site. Injection
of capsaicin alone did not significantly reduce subsequent histamine-, chloroquine-, or
SLIGRL-evoked scratching (Supplementary Fig. 3). However, when the conditioning
injection of capsaicin was administered together with QX-314, the scratching evoked by
subsequent histamine injection was abolished (Fig. 6a). Administration of capsaicin with
QX-314 also significantly reduced but did not eliminate scratching produced by subsequent
injections of chloroquine or SLIGRL (Fig. 6b,c) even though only a third of chloroquine
neurons are capsaicin sensitive (Fig. 5e), implying that the TRPV1+ subset of chloroquine-
sensitive neurons may have a particularly prominent role in eliciting behavioral itch
responses.
When QX-314 was administered together with AITC for the conditioning injection,
subsequent SLIGRL-evoked scratching was significantly reduced (Fig. 6c). Likewise,
chloroquine-evoked scratching was virtually abolished 30 minutes after injection of QX-314
together with AITC (Fig. 6b). In contrast, injection of QX-314 with AITC did not reduce
subsequent histamine-evoked scratching (Fig. 6a). In summary, chloroquine-and SLIGRL-
evoked scratching is effectively blocked when TRPA1+ (AITC-responsive) fibers are
electrically silenced. Histamine-evoked scratching, on the contrary, is largely abolished
when TRPV1+ fibers are electrically silenced but is unaffected when TRPA1+ (AITC-
responsive) fibers are blocked. Histamine itch is predominantly associated with TRPV1+
pruriceptor fibers, and non-histamine itch with TRPA1+ fibers.
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TRPV1+/TRPA1+ afferents are involved in itch inhibition
Cheek injection of capsaicin normally evokes only a wiping (pain) response without any
significant scratching (itch)26,31. We found, however, that cheek injection of capsaicin
(0.1%, 10 μl) produced significant scratching (itch) together with wiping (pain) when
TRPA1-responsive nociceptors were first silenced by conditioning coinjection of AITC
(0.15%, 20 μl) with 1% QX-314 (Fig. 7a). Injection of capsaicin (0.1%, 10 μl) 30 minutes
after 20 μl injection of AITC (0.15%), capsaicin (0.1%), QX-314, or vehicle (0.9% NaCl)
alone produced only wiping (Supplementary Fig. 4a). Capsaicin-evoked scratching
following coinjection of AITC (0.15%) with QX-314 was prevented when the conditioning
combination included histamine (100 μg) (Supplementary Fig. 3d). These data suggest that a
subset of TRPA1+ sensory neurons normally mask capsaicin-evoked itch, and that silencing
these neurons allows capsaicin to generate itch-related behavior through uninhibited
activation of TRPV1+ histaminergic itch fibers.
When we repeated the experiments using AITC (0.15%, 10 μl) as the test algogen (Fig. 7b)
we again observed that algogen-mediated electrical silencing, this time by coinjection of
capsaicin (0.1%) and QX-314, resulted in both wiping and scratching upon test injection of
AITC (Fig. 7b). The AITC-evoked scratching was largely reversed when chloroquine- and
capsaicin-responsive fibers were both silenced by a conditioning injection of chloroquine
(50 μg), capsaicin (0.1%) and QX-314 together (Supplementary Fig. 3e). These findings
suggest that a subset of TRPV1-expressing sensory neurons normally mask itch following
AITC activation of chloroquine-sensitive itch fibers.
Thus, silencing TRPA1+ fibers and silencing TRPV1+ fibers allow capsaicin and AITC,
respectively, to evoke scratching (itch) responses. Our interpretation is that there is a subset
of peripheral TRPV1+/TRPA1+ neurons that when activated normally inhibit or mask itch
via central inhibitory interneurons32, and whose silencing then allows either capsaicin or
AITC to abnormally evoke itch.
DISCUSSION
We selectively inhibited pain- and itch-related behaviors by targeting the membrane-
impermeant sodium channel blocker QX-314 into peripheral axon terminals of distinct
populations of trigeminal pruriceptors or nociceptors. The specific population silenced was
determined by the pattern of activation of particular large pore channels by different
pruritogens or algogens; TRPV1 for capsaicin and histamine, TRPA1 for AITC, chloroquine
and SLIGRL. We show by electrophysiological recording that activation of these large pore
channels by histamine and chloroquine enables sufficient permeation of QX-314 into
trigeminal neurons to block sodium currents, as previously shown for capsaicin19, and that
this effect is specific; only pruritogen-activated neurons are blocked. The fact that specific
TRP-channel blockers (TRPV1 for histamine and TRPA1 for chloroquine) can prevent
permeation of QX-314 indicates that it is TRP channel mediated. This has enabled us to
exploit the silencing of different afferents to tease out their functional sensitivity to defined
stimuli. This approach differs from interventions that only block a particular receptor (e.g.,
H1R, H4R)33 or channel (e.g. TRPA1)34 in that it targets action potential generation and
conduction of the activated axon, and differs from genetic targeted ablation of different
sensory neuronal subtypes35 in that it is temporary with no compensatory changes.
Utilizing this selective silencing strategy we reveal that fibers that mediate histamine and
non-histamine itch are functionally separable. Moreover we demonstrate that activation of
these itch-generating fibers is not required for eliciting normal responses to acute
mechanical and thermal stimuli. Our in vitro data confirm the presence of adult sensory
neurons that respond only to histamine or only to chloroquine.
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Separate afferent lines are described for histamine and cowhage itch16,36 and a distinct non-
histamine itch pathway activated by β-alanine17. Our data support, in addition, separate
functional pathways for histamine itch and itch mediated by the MrgprA3 and C11 ligands
chloroquine and SLIGRL, respectively. The separation of these afferents based on the
silencing approach was defined for a broad range of pruritogen concentrations for targeting
QX-314 into afferent terminals through activated TRP channels. At extremely high
concentrations (>90 mM) of pruritogen in vivo, however, an overlap did occur between
histamine and chloroquine populations. This cross-activation between the two populations
could be secondary to release of endogenous mediators from keratinocytes, mast cells or
other non-neuronal cells activated secondary to high-dose pruritogen administration, or it
could reflect a very limited sensitivity of the peripheral terminals of histaminergic
pruriceptors to chloroquine and SLIGRL, and of the non-histaminergic terminals to
histamine. Given that the high concentrations of the opposing pruritogen required to co-
activate the separate histamine or non-histamine responsive set of afferents are unlikely to
be found in most natural conditions29,30, we consider it probable that the two sets are
functionally distinct and normally act independently.
Our calcium imaging data also confirm the existence of distinct trigeminal and DRG neuron
populations that respond to either chloroquine or histamine at a range of doses in adult mice.
Prior in vitro experiments have shown that MrgprA3 lineage DRG neurons in juvenile (4-
week-old) mice respond both to chloroquine (1 mM) and histamine (50 μM)6. Similarly,
ablation of MrgprA3+ neurons in 5-week-old mice significantly attenuates both chloroquine-
and histamine-evoked scratching behavior15. However, a recent study that showed that the
proportion of DRG neurons responding to both histamine and chloroquine is markedly less
in 7 to 9-week-old mice compared to 3 to 4-week-old mice18. We interpret these collective
data as suggesting that in adult (2 to 4-month-old) mice, Mrgpra3+ neurons are likely
composed of pruriceptors with a differential sensitivity to, but not absolute selectivity for
chloroquine, and that these afferents normally contribute primarily to non-histaminergic
itch. Microneurographic studies in humans have identified a distinct set of histamine-
insensitive fibers activated during cowhage-evoked itch16. The finding that cowhage
spicules activate MrgprA3+ neurons suggests that a common pathway may mediate
chloroquine and cowhage itch15. However, cowhage spicules act promiscuously on many
nociceptor subtypes and may instead trigger itch nonspecifically through focal activation of
superficial nociceptor terminals37.
H1R and MrgprA3 receptors rely on downstream activation of TRPV1 or TRPA1 channels,
respectively, to generate itch behavior11,12,14, which is somewhat counterintuitive since
these TRP channels are also activated by algogens (capsaicin and AITC) that normally
produce pain. This raises questions both whether there are different subsets of TRPV1+ or
TRPA1+ neurons involved in processing pain or itch, and why pain normally predominates.
Our data show that histamine itch is mediated by TRPV1+ fibers that do not express
appreciable levels of TRPA1, since histamine itch is inhibited by silencing capsaicin-
activated fibers, but not by silencing AITC-activated fibers. This correlates with the
coincidence of capsaicin and histamine responsiveness in most histamine responsive
trigeminal neurons. Chloroquine or SLIGRL itch, in contrast, appears to be mediated mainly
by TRPA1+ fibers. But, using capsaicin-induced silencing and trigeminal neuron calcium
imaging we show that a subset of these fibers also coexpress TRPV1. TRPV1 is therefore
promiscuously expressed in nociceptors and both histaminergic and non-histaminergic
pruriceptors.
Electrical silencing of either histamine-sensitive or chloroquine-sensitive primary afferents
blocks itch but does not alter a wide range of pain-associated behaviors, suggesting that
while these primary afferent fibers are required for itch, as are GRPR+ neurons in the dorsal
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spinal cord35,38, they are not necessary for eliciting acute thermal or mechanical pain, as
also demonstrated for the MrgprA3+ population15. Our data do not rule out the possibility,
though, that activation of some histamine-sensitive or chloroquine-sensitive fibers might be
sufficient to produce pain. For example, histamine can evoke pain in rodents and
humans39,40, particularly in bradykinin-sensitized nociceptors41. We also find a group of
peripheral neurons expressing both TRPA1 and TRPV1 that appear to be involved in a
functional inhibition or masking of itch, since silencing either TRPA1+ fibers or TRPV1+
fibers now allows capsaicin or AITC to evoke itch, rather than pain. Consistent with this,
when nociceptive sensitivity is reduced by abolishing vesicular glutamate transporter type 2
(VGLUT2)-dependent synaptic glutamate release in nociceptors, intradermal capsaicin
injection is also now able to generate scratching42. We propose, therefore, that the algogen-
evoked itch that follows electrical silencing of contra-algogen-responsive fibers may
represent a pain-to-itch synesthesia produced only when TRPV1+ histaminergic pruriceptors
or TRPA1+ non-histaminergic pruriceptors are activated and a normally itch-inhibiting
subset of TRPV1+/TRPA1+ nociceptors is silenced (Supplementary Fig. 7). In the absence
of such silencing, the combination of activation of nociceptive pathways and inhibition of
itch by TRPV1 or TRPA1 expressing nociceptors will lead to pain dominating as a
sensation.
Our findings suggest that primary afferent itch-generating neurons encode functionally
distinct histamine and chloroquine itch pathways (Supplementary Fig. 7). In addition to
revealing modality specificity and functional specialization of somatosensory afferents, our
findings could also help direct development of new treatments for itch. Administration of
QX-314 may be an effective treatment for pruritus caused by either histamine or non-
histamine pruritogens if they are associated with sufficient activation of TRPV1 or TRPA1.
Alternatively, because large-pore channels are present in both histamine- and chloroquine-
sensitive pruriceptors, targeting QX-314 broadly into these fibers via co-activation of both
TRPV1 and TRPA1 channels, for example by using a non-pungent TRPV1/TRPA1 co-
activator23,24,43, may have therapeutic promise for preventing or blocking both histamine-
evoked itch and histamine-independent itch, although at the expense of also producing
analgesia.
METHODS
Combined Calcium Imaging and Voltage Clamp recordings
Cell Culture—Trigeminal neuron cultures were prepared from adult (2 to 3-month-old)
CD1 mice44. In short, trigeminal neurons were removed and placed into HBSS and 1%
penicillin–streptomycin (Sigma), then digested in 5mg/ml collagenase, 1mg/ml Dispase II
(Roche, Indianapolis, IN). Cells were triturated in the presence of DNAse I inhibitor (50U)
and centrifuged through 10% BSA (Sigma). The cell pellet was resuspended in 1ml
Neurobasal (Sigma) containing B27 supplement (Invitrogen), penicillin and streptomycin
(Sigma), 10μM AraC. Cells were plated onto poly-d-lysine (500ug/ml) and laminin (5 mg/
ml) coated 35 mm tissue culture dishes (Becton Dickinson) at 8000–9000 per dish, at 37°C,
5% carbon dioxide.
Ratiometric calcium imaging—Cultured adult trigeminal neurons were loaded for 45–
60 minutes with 1 μM fura-2 AM (stock in DMSO) in a bath solution composed of (in mM):
145 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 Glucose, 10 HEPES and then rinsed for 45–60
minutes for de-esterification of intracellular AM esters. Neurons were perfused continuously
at 2 ml/min and examined with an inverted microscope (Eclipse Ti) equipped with Epi-Fl
attachment; perfect focus system (Nikon, Japan) and Exi Aqua monochromator (QImaging).
Intracellular [Ca2+]i was measured fluorometrically as an absorbance ratio at 340 nm and
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380 nm (3F340/380) (510 nm for emission) (Lambda DG4, Sutter Instruments). Images
were taken every 1 second, were monitored online and analyzed offline using Nikon
Elements AR Software (Nikon). Histamine (100μM) and chloroquine (100μM) were briefly
bath applied (60 s) using a fast-step valve control perfusion system (Harvard Apparatus). In
all responsive neurons, the changes in ratio (ΔF) following application of histamine and
chloroquine were larger than 0.1ΔF and were easily distinguishable from optic noise, which
was less than 0.025ΔF. Whole cell voltage clamp recordings were then performed from the
responsive cells (histamine-positive or chloroquine-positive) and non-responsive cells
(histamine-negative or chloroquine-negative).
Electrophysiology—For electrophysiological recordings of transmembrane sodium
currents, in order to decrease driving force for sodium the solutions were replaced after
completing calcium imaging measurements to thereafter contain (in mM): 60 NaCl, 4 KCl, 1
MgCl2, 2 CaCl2, 0.1 CdCl2, 10 HEPES, 10 Glucose, 5 4-AP,60 Choline chloride, 15 TEA-
Cl, (pH, 7.4). Pipette solution contained (in mM): 110 CsCl, 25 CsOH, 2 MgCl2, 1 CaCl2,
11 EGTA, 10 HEPES, (pH = 7.4 with CsOH). Recordings were performed using a
Multiclamp 700 B amplifier (Molecular Devices) at room temperature (22 ± 2°C). Data
were low pass filtered at 1 kHz (−3 dB, 4 pole Bessel filter) and sampled at 10 kHz. Patch
pipettes were pulled from thick-walled borosilicate glass capillaries (1.5 mm outer diameter,
Sutter Instrument) on a Sutter Instrument P-1000 puller (Novato, CA) and had a resistance
of 2–5 MΩ. Pipette potential was zeroed before seal formation and membrane potential not
corrected for the small liquid junction potential (−2.2 mV). Care was taken to maintain
membrane access resistance as low as possible (usually 3–7 MΩ and always less than 10
MΩ). Capacity currents were cancelled and series resistance 80% compensated. Linear
leakage currents were digitally subtracted on-line using a P/4 procedure. Command voltage
protocols were generated on-line with a Digidata 1200 A/D interface (Molecular Devices).
Data were digitized on-line using pCLAMP 10.2 (Molecular Devices). Data averaging and
peak detection were made using pCLAMP 10.2 software (Molecular Devices). Data were
fitted using QPlot.
For these experiments we have used data only from neurons in which input resistance and
leak current did not significantly change during 10 minutes of drug application (20 min of
recording). Due to the relatively low number of responsive cells and long and complex
protocol of subsequent electrophysiological recording we have used data from 3 cells per
group (7 groups).
Calcium Imaging (alone) Experiments
All dissections were performed on adult (2 to 4-month-old) male CD-1 mice. The calcium-
indicator dye Fura-2 AM was introduced at 2 μg/ml for 30 minutes at room temperature,
washed, and analyzed on a Nikon Eclipse Ti inverted microscope with exi-aqua CCD
camera with NIS-elements AR 3.10 software. Each cell was given three minutes to recover
from each pruritogen exposure, and 8 minutes to recover between exposure to AITC and
capsaicin. Each exposure was for sixty seconds, except for capsaicin, which was exposed
only for 10 seconds. Pruritogens were locally applied, with the perfusion opening placed
approximately 150 microns from the field of view, and preliminary exposure to standard
extracellular solution was employed prior to exposure to reagents made in SES. Pruritogen
order was assigned at random (coin toss) for each plate, and no order effects were observed
between differently ordered groups.
Behavioral Studies
All animal procedures were approved by the Boston Children’s Hospital Animal Care and
Use Committee. Naïve adult (2 to 4-month-old) male CD-1 mice (Charles River
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Laboratories) housed in groups of 5 using a normal 12-hour light/dark cycle were used.
Animals were fully habituated to handling prior to all experimental procedures and were
randomly assigned to experimental groups. The day before beginning itch experiments, mice
were briefly anesthetized by inhalation of 1–2% isofluorane and a ~1 cm2 area of hair was
shaved on the right cheek of each mouse. Capsaicin (Sigma-Aldrich, St. Louis MO) was
freshly prepared by dilution in vehicle (20% ethanol, 5% Tween 20 in saline; 10 ml). All
other drug solutions were prepared freshly in normal saline (0.9% NaCl).
Itch Assay—Mice received intradermal (id) microinjection of pruritogen, algogen,
QX-314, vehicle or a combination of pruritogen or algogen together with QX-314
intradermally in the cheek. To ensure proper intradermal injection, needle puncture with a
28g needle was initiated bevel-up at 5° to the plane of taut skin until initial penetration, then
inserted horizontally until the needle tip was 0.5 cm beyond the point of insertion before
intradermal evacuation of syringe contents. Correct injection was confirmed by presence of
a slightly domed bulla immediately following removal of needle (Supplementary Fig. 2c).
For sequential injection experiments, the intradermal bullae of the conditioning (first)
injection were outlined with fine-tip permanent marker to denote the extent of intradermal
drug distribution, thus providing visible drug distribution boundaries for subsequent
injections (Supplementary Fig. 2). Animals not receiving proper drug injections were noted
and excluded from the study prior to observation. Immediately after conditioning injection,
mice were placed in in a custom-built itch observation apparatus and video recorded during
the mouse dark cycle as previously described26. Scratches and/or wipes subsequently
quantified by blinded observers.
Von Frey assay—Mice were assessed manually using the up-down method to determine
the median 50% (5/10) withdrawal threshold45.
Radiant heat (Hargreaves) assay—Radiant heat withdrawal threshold was determined
using the Plantar Analgesia Meter (IITC Life Science, Inc.) according to methods previously
described46.
Focal cold plantar (Brenner) assay—Latency to remove hindpaw from focally applied
cold stimulus was performed according to methods previously described27 only using 3/8″
thick (4.78 mm, as measured by electronic caliper) Neoceram™ N-0 thermal-shock-resistant
glass (Nippon Electric Glass Co., Ltd.).
Adhesive dot plantar tactile (“sticky tape”) assay—Latency to bite, lick, or attempt
removal of a 9 mm diameter circular adhesive Microtube Tough-Spots® label (Diversified
Biotech) was performed according to methods previously described28, only using hindpaw
instead of forepaw for application of stimulus.
Statistical Analysis
Sample sizes for all experiments were chosen according to standard practice in the field. For
electrophysiological experiments the significance of the effect was calculated using two-way
ANOVA non-parametric test followed by Bonferroni post-test. Comparison of group means
for behavior studies was performed using Student’s t-test. All bar graphs are plotted as mean
± standard error of the mean (SEM). For behavioral studies, “n” represents the total number
of mice used in each group.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Application of pruritogens leads to a QX-314-mediated blockade of sodium currents
selectively in pruritogen-sensitive trigeminal ganglion (TG) neurons
(a) Photomicrography (left) and representative traces (right) of changes in intracellular
calcium concentration recorded from cultured trigeminal ganglia neurons at left. Red arrow
indicates small trigeminal neuron that responded (red trace) to histamine (60 seconds, 100
μM). Blue arrow indicates cell that did not respond (blue trace) to application of histamine.
Dotted line indicates the time point of the photomicrography frame. (b) Representative,
normalized traces of sodium currents recorded from histamine-positive (left) and histamine-
negative (right) neurons before (black) and 10 minutes after (green) application of 100 μM
histamine together with 5 mM QX-314. (c) Time course of the changes in amplitude of peak
sodium current. The specific TRPV1 antagonist capsazepine (20 μM) abolished the
histamine/QX-314-mediated decrease in sodium current. Results are mean ± SEM of peak
sodium current relative to control (n = 3 for each group. For statistical analysis see
Supplementary Table 2). (d) Photomicrography (left) and representative traces (right, dotted
line indicates the time point of the photomicrography frame) of changes in intracellular
calcium concentration following application of chloroquine (60 seconds, 100 μM). (e)
Representative, normalized traces of sodium current recorded from chloroquine-positive
(left) and chloroquine-negative (right) neurons before (black) and 10 minutes after (green)
application of 100 μM chloroquine together with 5 mM of QX-314. (f). Time course of
changes in amplitude of peak sodium current. The specific TRPA1 antagonist HC-030031
(100 μM) abolished chloroquine/QX-314-mediated decrease in sodium current. Results are
mean ± SEM of peak sodium current relative to control (n = 3 for each group. For statistical
analysis see Supplementary Table 4).
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Figure 2. Co-administration of QX-314 and pruritogens inhibits subsequent pruritogen-evoked
scratching
(a, c, e) Sequential pruritogen cheek injections at 30-minute inter-stimulus intervals (ISI)
evoke similar levels of cheek scratching (itch) bouts. (b, d, f) Pruritogen-evoked scratching
is inhibited 30-minutes after conditioning injection of pruritogen together with 1% QX-314.
(a) Conditioning injection: histamine (100 μg/20 μl), total scratching bouts in 30 minutes
(TSB/30 minutes) = 64.3 ± 7.5 bouts. Test injection: histamine (100 μg/10 μl), TSB/30
minutes = 49.2 ± 9.7, P > 0.05, n = 6, degrees of freedom (d.f.) = 10. (b) Conditioning
injection: histamine (100 μg/20 μl) + 1% QX-314, TSB/30 minutes = 56.0 ± 8.3. Test
injection: histamine (100 μg/10 μl), TSB/30 minutes = 7.5 ± 3.8, P < 0.001, n = 6, d.f. = 10.
(c) Conditioning injection: chloroquine (CQ, 50 μg/20 μl), TSB/30 minutes = 103.0 ± 19.1.
Test injection: chloroquine (50 μg/10 μl), TSB/30 minutes = 109.0 ± 20.8, P > 0.05, n = 7,
d.f. = 12. (d) Conditioning injection: chloroquine (50 μg/20 μl) + 1% QX-314, TSB/30
minutes = 110.0 ± 13.7. Test injection: chloroquine (50 μg/10 μl), TSB/30 minutes = 31.8 ±
13.3, P < 0.01, n = 6, d.f. = 10. (e) Conditioning injection: SLIGRL (50 μg/20 μl), TSB/30
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minutes = 80.8 ± 9.6. Test injection: SLIGRL (50 μg/10 μl), TSB/30 minutes = 71.4 ± 12.0,
P > 0.05, n=5, d.f. = 8. (f) Conditioning injection: SLIGRL (50 μg/20 μl) + 1% QX-314,
TSB/30 minutes = 71.2 ± 16.1. Test injection: SLIGRL (50 μg/10 μl), TSB/30 minutes =
17.7 ± 8.0, P < 0.05, n = 6, d.f. = 10. Figure results are mean ± SEM of total scratching
bouts per minute for 30 minutes after conditioning injection and test injection. Total
scratching bouts in 30 minutes (TSB/30 minutes) are mean ± SEM of total scratching bouts
in 30 minutes following injection. P-values represent comparison of value of mean total
scratching bouts in 30 minutes evoked by test injection to those evoked by conditioning
injection.
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Figure 3. Silencing pruritogen-responsive neurons does not alter behavioral responses to non-
itch stimuli
Forelimb wipes (pain-related behavior) evoked by (a) capsaicin (0.1%, 10 μl) and (b) AITC
(0.15%, 10 μl) 30 minutes after cheek conditioning injections of vehicle or 1% QX-314
together with pruritogens (histamine, chloroquine (CQ)) or algogens (capsaicin, AITC).
Hindpaw withdrawal to (c) punctate mechanical (von Frey) stimulus, (d) a radiant heat (52°
C) stimulus, or (e) focally applied cold stimulus (see online methods) 30 minutes after
intraplantar conditioning injections of vehicle or 1% QX-314 together with pruritogens or
algogens. (f) Latency to bite, lick or attempt removal of an adhesive dot on the plantar
surface of the hindpaw 30 minutes after intraplantar conditioning injections of vehicle, 1%
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QX-314 together with pruritogens or algogens was compared with a group receiving saline
or intraplantar injection of 5% lidocaine (after 5 minutes). P-values represent comparison to
vehicle (white column) value (not significant, P > 0.05; *, P < 0.05; ** P < 0.01). Error bars,
SEM. n = 5–7 for all groups.
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Figure 4. Distinct primary afferents mediate histaminergic itch and non-histaminergic itch
Pruritogen-evoked cheek scratching (itch) bouts 30 minutes after different conditioning
injections indicated at the x-axes. (a) Intradermal test injection of histamine (100 μg/10 μl)
alone, (b) chloroquine (CQ, 50 μg/10 μl) alone or (c) SLIGRL (50 μg/10 μl) alone 30
minutes after conditioning injection of vehicle or pruritogens together with 1% QX-314 P-
values represent comparison to vehicle (white column) value (not significant, P > 0.05; *, P
< 0.05; ** P < 0.01). Error bars, SEM. n = 5–7 for all groups.
Roberson et al. Page 21
Nat Neurosci. Author manuscript; available in PMC 2014 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. Proportional representation of coincident trigeminal cell responses to low dose
chloroquine and histamine, and their overlapping responsiveness with capsaicin and AITC
Venn diagram of calcium responses of 564 cultured trigeminal (TG) neurons to 10 μM
histamine, 10 μM chloroquine (CQ), 1 μM capsaicin, and 100 μM AITC. (a) Histamine (10
μM) activated 23 of 564 TG neurons, while 17 responded to 10 μM chloroquine. Among
histamine-activated cells 19 of 23 responded to histamine but not chloroquine, and 4 of 23
responded to both histamine and chloroquine. For TG cells responding to chloroquine 13 of
17 responded to chloroquine but not histamine. (b) Capsaicin activated 235 of 564 cells.
Among histamine responsive cells, 16 of 23 also responded to capsaicin. (c) AITC activated
161 of 564 TG neurons, and more than half of chloroquine-responding cells (9 of 17)
responded to AITC. (d) AITC activated 9 of 23 of histamine-responding cells. (e) Capsaicin
activated 5 of 17 of chloroquine-responsive TG neurons.
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Figure 6. Selective silencing of nociceptor populations differentially inhibits histamine itch and
non-histamine Itch
Cheek scratching (itch) following intradermal test injection of (a) histamine (100 μg/10 μl)
alone (n = 6), (b) chloroquine (CQ, 50 μg/10 μl) alone (n = 6–7), and (c) SLIGRL (50 μg/10
μl) (n = 5–6) 30 minutes after a conditioning injection of vehicle (0.9% NaCl, 20 μl) or 1%
QX-314 together with capsaicin or AITC. P-values represent comparison to vehicle (white
column) value (not significant, P > 0.05; *, P < 0.05; **, P < 0.01; *** P < 0.001). Error
bars, SEM.
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Figure 7. TRPV1+/TRPA1+ fibers suppress itch
(a) Hindlimb scratching (itch) evoked by capsaicin (0.1%, 10 μl) thirty-minutes after
intradermal injection of vehicle (0.9% NaCl, 20 μl), capsaicin (0.1%) together with 1%
QX-314 (20 μl) or AITC (0.15%) together with 1% QX-314 (20 μl). Note the significant
increase in capsaicin-mediated scratching following application of AITC with QX-314. (b)
Thirty-minutes after injection of vehicle (0.9% NaCl, 20 μl) intradermal cheek injection of
AITC (0.15%, 10 μl) generated little hindlimb scratching over the next 30 minutes and this
was not changed following a conditioning injection of AITC together with 1% QX-314.
However, the AITC evoked scratching increased following intradermal cheek injection of
capsaicin (0.1%) together with 1% QX-314 (20 μl). P-values represent comparison to
vehicle value (not significant, P > 0.05; *, P < 0.05). Error bars, SEM. n = 6 for all groups.
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